Gamida Cell Completes Enrollment for Phase I/II Of NiCord

Israeli medical company Gamida Cell will move forward with testing its second pipeline product – NiCord, for treatment of blood cancer and other blood-related conditions. The trials are expected to show results within 6 months. This announcement comes two weeks after the company’s announcement of its contact with pharmaceutical giant Pfizer, with intention of commercializing Gamida Cell’s flagship product – StemEX.